Q1. Which of the following best explains how alternative RNA splicing contributes to drug resistance in prostate cancer?
- (1) It allows for the removal of all exons, resulting in a completely non-functional Androgen Receptor (AR), leading to resistance.
- (2) It enables the production of Androgen Receptor (AR) variants that lack the ligand-binding domain, allowing them to remain constitutively active despite androgen deprivation therapy.
- (3) Alternative splicing reduces the expression of AR protein by increasing the retention of introns, making the cancer cells insensitive to androgen signals.
- (4) It promotes the random recombination of exons and introns, leading to the formation of entirely new protein structures that evade targeted therapies.
- (5) Question not attempted